Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 26;15(12):2676.
doi: 10.3390/pharmaceutics15122676.

Pharmacokinetic Study of Islatravir and Etonogestrel Implants in Macaques

Affiliations

Pharmacokinetic Study of Islatravir and Etonogestrel Implants in Macaques

Michele B Daly et al. Pharmaceutics. .

Abstract

The prevention of HIV and unintended pregnancies is a public health priority. Multi-purpose prevention technologies capable of long-acting HIV and pregnancy prevention are desirable for women. Here, we utilized a preclinical macaque model to evaluate the pharmacokinetics of biodegradable ε-polycaprolactone implants delivering the antiretroviral islatravir (ISL) and the contraceptive etonogestrel (ENG). Three implants were tested: ISL-62 mg, ISL-98 mg, and ENG-33 mg. Animals received one or two ISL-eluting implants, with doses of 42, 66, or 108 µg of ISL/day with or without an additional ENG-33 mg implant (31 µg/day). Drug release increased linearly with dose with median [range] plasma ISL levels of 1.3 [1.0-2.5], 1.9 [1.2-6.3] and 2.8 [2.3-11.6], respectively. The ISL-62 and 98 mg implants demonstrated stable drug release over three months with ISL-triphosphate (ISL-TP) concentr54ations in PBMCs above levels predicted to be efficacious for PrEP. Similarly, ENG implants demonstrated sustained drug release with median [range] plasma ENG levels of 495 [229-1110] pg/mL, which suppressed progesterone within two weeks and showed no evidence of altering ISL pharmacokinetics. Two of the six ISL-98 mg implants broke during the study and induced implant-site reactions, whereas no reactions were observed with intact implants. We show that ISL and ENG biodegradable implants are safe and yield sufficient drug levels to achieve prevention targets. The evaluation of optimized implants with increased mechanical robustness is underway for improved durability and vaginal efficacy in a SHIV challenge model.

Keywords: HIV pre-exposure prophylaxis; biodegradable implant; etonogestrel; islatravir; multipurpose prevention technologies.

PubMed Disclaimer

Conflict of interest statement

The authors (L.M.J., A.v.d.S., L.L., A.K. and E.H.L.) are inventors on pending patent applications filed by RTI. Author Ariane van der Straten is employed by the company ASTRA Consulting. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
In vitro drug release from PCL implants. (A) Daily in vitro release profiles of ISL from implants run in parallel with the in vivo study in macaques with average release rates of 41.9 ± 5.5 µg/day (ISL-62 mg) and 65.6 ± 8.2 µg/day (ISL-98 mg). (B) Daily in vitro release profile of ENG from implants run in parallel with the in vivo study with an average release rate of 31.1 ± 9.6 µg/day.
Figure 2
Figure 2
Study Design. (A) The first group of 3 macaques received ISL-62 mg implant (right arm) to assess the low ISL dose and a month later received an ISL-98 mg implant in their left arm to evaluate the high ISL dose. (B) The second group of 3 macaques received ISL-98 mg implant (right arm) to assess the mid ISL dose and received an ENG-33 mg implant in their left arm a month later. The ISL-98 mg implant was removed at 3 months. The ENG implant was removed after 6 months.
Figure 3
Figure 3
Pharmacokinetics of ISL and ISL-TP. (A) Median [range] plasma ISL and (B) PBMC ISL-TP levels for the low-dose ISL-62 mg (blue), mid-dose ISL-98 mg (red), and high-dose ISL-62 and ISL-98 mg (green). Day zero for ISL-62 mg and ISL-98 mg animals was the day of the first implantation. Day zero for the ISL-62 & ISL-98 mg was the day of the second implantation. The pharmacokinetic benchmark of 50 fmol ISL-TP/106 PBMCs (Target) and lower limit of quantification (LLOQ) are shown with dashed lines. (C) Dose linearity between the in vitro release rate and plasma ISL (left axis, circles) and PBMC ISL-TP (right axis, squares). (D) Pharmacokinetic tail of ISL plasma ISL (top) and PBMC ISL-TP (bottom) after removal of ISL-98 mg from the mid-dose group.
Figure 4
Figure 4
Plasma progesterone (left axis, red) and ENG (right axis, purple) in macaques that received ISL-98 mg and ENG-33 mg implants.
Figure 5
Figure 5
The effect of ISL and ENG co-implantation on ISL pharmacokinetics was determined by evaluating ISL analytes. (A) Plasma ISL, (B) PBMC ISL-TP, and (C) mucosal tissue ISL-TP when animals had a single ISL-98 mg implant (open shapes) compared to after co-implantation with ENG (red shapes). (D) Ratios of ISL-TP to the natural nucleotide competitor, dATP, were determined for each tissue. Each individual animal (n = 3) is shown with a different shape.
Figure 6
Figure 6
Implant site reactions were scored weekly for erythema and edema using a modified Draize scale. (A) Heat map of weekly Draize scoring of implant site for each animal (columns PT1-PT6) and each implant (ISL-62, ISL-98 or ENG-33 mg). Colors indicate severity of implant site reaction (0 = none/green, 1 = mid, 2 = well-defined, 3 = moderate, 4 = severe/red). Red boxes indicate when ISL-98 mg implants were deemed broken. (B) Median Draize scores for ENG-33 (purple), ISL-62 (blue), intact ISL-98 mg implants (red, unfilled box), and broken ISL-98 mg implants (red, filled box).

References

    1. GBD 2015 HIV Collaborators Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: The Global Burden of Disease Study 2015. Lancet HIV. 2016;3:e361–e387. doi: 10.1016/S2352-3018(16)30087-X. - DOI - PMC - PubMed
    1. UNAIDS Gender Every Minute. [(accessed on 20 June 2023)]. Available online: https://www.unaids.org/sites/default/files/20120607_infographic_gender-e....
    1. Wulandari L.P.L., He S.Y., Fairley C.K., Bavinton B.R., Marie-Schmidt H., Wiseman V., Guy R., Tang W., Zhang L., Ong J.J. Preferences for pre-exposure prophylaxis for HIV: A systematic review of discrete choice experiments. EClinicalMedicine. 2022;51:101507. doi: 10.1016/j.eclinm.2022.101507. - DOI - PMC - PubMed
    1. Quaife M., Eakle R., Cabrera Escobar M.A., Vickerman P., Kilbourne-Brook M., Mvundura M., Delany-Moretlwe S., Terris-Prestholt F. Divergent Preferences for HIV Prevention: A Discrete Choice Experiment for Multipurpose HIV Prevention Products in South Africa. Med. Decis. Mak. 2018;38:120–133. doi: 10.1177/0272989X17729376. - DOI - PubMed
    1. Browne E.N., Montgomery E.T., Mansfield C., Boeri M., Mange B., Beksinska M., Schwartz J.L., Clark M.R., Doncel G.F., Smit J., et al. Efficacy is Not Everything: Eliciting Women’s Preferences for a Vaginal HIV Prevention Product Using a Discrete-Choice Experiment. AIDS Behav. 2020;24:1443–1451. doi: 10.1007/s10461-019-02715-1. - DOI - PMC - PubMed

LinkOut - more resources